CoChat

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, or statin, that has been developed for the treatment of dyslipidemia.Objective This study assessed the metabolism, excretion, and pharmacokinetics of a single oral dose of radiolabeled rosuvastatin ([14C]-rosuvastatin) in healthy volunteers.Methods This was a nonrandomized, open-label, single-day trial. Healthy adult male volunteers were given a single oral dose of [14C]-rosuvastatin 20 mg (20 mL [14C]-rosuvastatin solution, nominally containing 50 microCi radioactivity). Blood, urine, and fecal samples were collected up to 10 days after dosing. Tolerability assessments were made up to 10 days after dosing (trial completion) and at a follow-up visit within 14 days of trial completion.Results Six white male volunteers aged 36 to 52 years (mean, 43.7 years) participated in the trial. The geometric mean peak plasma concentration (C(max)) of rosuvastatin was 6.06 ng/mL and was reached at a median of 5 hours after dosing. At C(max), rosuvastatin accounted for approximately 50% of the circulating radioactive material. Approximately 90% of the rosuvastatin dose was recovered in feces, with the remainder recovered in urine. The majority of the dose (approximately 70%) was recovered within 72 hours after dosing; excretion was complete by 10 days after dosing. Metabolite profiles in feces indicated that rosuvastatin was excreted largely unchanged (76.8% of the dose). Two metabolites-rosuvastatin-5S-lactone and N-desmethyl rosuvastatin-were present in excreta. [14C]-rosuvastatin was well tolerated; 2 volunteers reported 4 mild adverse events that resolved without treatment.Conclusions The majority of the rosuvastatin dose was excreted unchanged. Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0149-2918(03)80336-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. McCormick, 2000, ZD4522—an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems, J Clin Pharmacol, 40, 1055

Cited by

See all 286

Metadata

Authors
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E.
Affiliations
AstraZeneca (United Kingdom) (GB)
Corresponding author
Martin, Paul D.
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2003-11
Volume
25
Issue
11
Pages
2822-2835
ISSN
0149-2918 (ISSN-L)
OpenAlex
W2022507089
Cited by
286
References
20
Citations by year
2026: 10 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 11 · 2021: 13 · 2020: 15 · 2019: 12 · 2018: 19 · 2017: 9 · 2016: 14 · 2015: 23 · 2014: 16 · 2013: 20 · 2012: 13
FWCI
9.13
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cell Science Research Foundation
  • Shionogi
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
rosuvastatin, pharmacokinetics, drug metabolism, excretion, radiolabeled drug, statins, fecal excretion, urinary excretion, absolute bioavailability, tolerability
MeSH terms
Rosuvastatin Calcium, Adult, Biological Availability, Carbon Isotopes, Chromatography, High Pressure Liquid, Fluorobenzenes, Half-Life, Humans, Male, Metabolic Clearance Rate, Middle Aged, Pyrimidines, Sulfonamides, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. https://app.cochat.ai/papers/10.1016/s0149-2918(03)80336-3
The paper
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clinical Therapeutics. https://doi.org/10.1016/s0149-2918(03)80336-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.